Co-Diagnostics (NASDAQ:CODX) Issues Earnings Results

Co-Diagnostics (NASDAQ:CODX) announced its quarterly earnings data on Thursday. The company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.02), Zacks reports. Co-Diagnostics had a negative return on equity of 54.94% and a negative net margin of 563.93%.

Co-Diagnostics Price Performance

NASDAQ:CODX traded down $0.03 during mid-day trading on Thursday, reaching $0.39. The stock had a trading volume of 705,748 shares, compared to its average volume of 181,234. The company has a market capitalization of $12.45 million, a price-to-earnings ratio of -0.28 and a beta of 1.29. Co-Diagnostics has a 1-year low of $0.34 and a 1-year high of $2.23. The stock’s 50 day simple moving average is $0.63 and its two-hundred day simple moving average is $0.90.

About Co-Diagnostics

Co-Diagnostics, Inc, a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting.